Celldex Therapeutics Investor Relations Material

Celldex Therapeutics, Inc. is a biopharmaceutical company specializing in the development of therapeutic monoclonal and bispecific antibodies. These antibodies are designed to treat a range of serious conditions, including inflammatory, allergic, and autoimmune diseases. The company's lead program focuses on developing barzolvolimab, a monoclonal antibody targeting KIT, a key receptor tyrosine kinase involved in mast cell function, which is crucial in the onset and progression of various severe diseases. Celldex Therapeutics is headquartered in Hampton, New Jersey, and its shares are listed on the NASDAQ.